5.63
price down icon0.88%   -0.05
after-market 시간 외 거래: 5.75 0.12 +2.13%
loading
전일 마감가:
$5.68
열려 있는:
$5.73
하루 거래량:
18,438
Relative Volume:
0.12
시가총액:
$3.27M
수익:
$644.60K
순이익/손실:
$-9.87M
주가수익비율:
-0.00672
EPS:
-837.9618
순현금흐름:
$-9.02M
1주 성능:
-15.47%
1개월 성능:
+1.44%
6개월 성능:
-80.92%
1년 성능:
-93.43%
1일 변동 폭
Value
$5.62
$5.895
1주일 범위
Value
$5.5406
$6.6589
52주 변동 폭
Value
$4.71
$220.25

Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile

Name
명칭
Biodexa Pharmaceuticals Plc Adr
Name
전화
-
Name
주소
-
Name
직원
16
Name
트위터
Name
다음 수익 날짜
2024-06-13
Name
최신 SEC 제출 서류
Name
BDRX's Discussions on Twitter

Biodexa Pharmaceuticals Plc Adr 주식(BDRX)의 최신 뉴스

pulisher
Nov 01, 2024

Biodexa Pharmaceuticals Submits SEC Filing with Auditors’ Nod - TipRanks

Nov 01, 2024
pulisher
Oct 29, 2024

BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm - GlobeNewswire Inc.

Oct 29, 2024
pulisher
Oct 17, 2024

Biodexa reports promising glioblastoma trial results - Investing.com

Oct 17, 2024
pulisher
Oct 17, 2024

Biodexa Pharmaceuticals releases patient updates on PFS, OS from MAGIC-1 study - TipRanks

Oct 17, 2024
pulisher
Oct 17, 2024

Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer - StockTitan

Oct 17, 2024
pulisher
Oct 16, 2024

Stock Surge: Biodexa Pharmaceuticals Plc ADR (BDRX) Closes at 5.01, Marking a -4.21 Increase/Decrease - The Dwinnex

Oct 16, 2024
pulisher
Oct 15, 2024

Biodexa Pharmaceuticals Secures Nasdaq Compliance Extension - TipRanks

Oct 15, 2024
pulisher
Oct 15, 2024

Biodexa secures Nasdaq listing extension - Investing.com

Oct 15, 2024
pulisher
Oct 15, 2024

Biodexa Pharmaceuticals granted extension to regain compliance with Nasdaq - TipRanks

Oct 15, 2024
pulisher
Oct 15, 2024

Biodexa secures Nasdaq listing extension By Investing.com - Investing.com UK

Oct 15, 2024
pulisher
Oct 15, 2024

Biodexa Announces Successful Appeal of Nasdaq Delisting - StockTitan

Oct 15, 2024
pulisher
Oct 05, 2024

Biodexa provides update on PFS, OS in Phase 1 study of MTX110 in rGBM - TipRanks

Oct 05, 2024
pulisher
Oct 04, 2024

Biodexa reports survival rates in glioblastoma study - Investing.com India

Oct 04, 2024
pulisher
Oct 04, 2024

Biodexa reports updated Phase 1 data from glioblastoma study (NASDAQ:BDRX) - Seeking Alpha

Oct 04, 2024
pulisher
Oct 04, 2024

Biodexa’s MTX110 Shows Promise in Brain Cancer Study - TipRanks

Oct 04, 2024
pulisher
Oct 04, 2024

Biodexa reports survival rates in glioblastoma study By Investing.com - Investing.com UK

Oct 04, 2024
pulisher
Oct 04, 2024

Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma - StockTitan

Oct 04, 2024
pulisher
Oct 03, 2024

Ratio Analysis: Unpacking Biodexa Pharmaceuticals Plc ADR (BDRX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 03, 2024
pulisher
Oct 02, 2024

Biodexa Pharmaceuticals Plc ADR (BDRX) Stock: A Year of Declines and Increases - The InvestChronicle

Oct 02, 2024
pulisher
Sep 26, 2024

Should investors be concerned about BDRX’s high price-to-sales ratio? - US Post News

Sep 26, 2024
pulisher
Sep 26, 2024

Interim results for the six months ended June 30, 2024 - StockTitan

Sep 26, 2024
pulisher
Sep 26, 2024

Biodexa Pharmaceuticals Reports Promising H1 2024 Results - TipRanks

Sep 26, 2024
pulisher
Sep 23, 2024

Market Watch Highlights: Biodexa Pharmaceuticals Plc ADR (BDRX) Ends on an Downturn Note at 0.29 - The Dwinnex

Sep 23, 2024
pulisher
Sep 19, 2024

Biodexa Pharmaceuticals announces ADR ratio change - Investing.com

Sep 19, 2024
pulisher
Sep 19, 2024

ADR Ratio Change - Markets Insider

Sep 19, 2024
pulisher
Sep 19, 2024

Biodexa Pharmaceuticals Announces ADR Ratio Change - TipRanks

Sep 19, 2024
pulisher
Sep 16, 2024

Biodexa secures full access to cancer research grant - Investing.com

Sep 16, 2024
pulisher
Sep 16, 2024

Biodexa Pharmaceuticals Advances FAP Treatment - TipRanks

Sep 16, 2024
pulisher
Sep 04, 2024

BDRX Stock on the Rise: A Promising Investment - The InvestChronicle

Sep 04, 2024
pulisher
Sep 02, 2024

Financial Health Report: Biodexa Pharmaceuticals Plc ADR (BDRX)’s Ratios Tell a Tale - The Dwinnex

Sep 02, 2024
pulisher
Sep 02, 2024

Biodexa Pharmaceuticals Plc ADR (BDRX) produces promising results - US Post News

Sep 02, 2024
pulisher
Sep 02, 2024

Investors in cash trouble should check out Biodexa Pharmaceuticals Plc ADR (BDRX) - SETE News

Sep 02, 2024
pulisher
Aug 30, 2024

Receipt of Nasdaq Delisting DeterminationPlans to Appeal - StockTitan

Aug 30, 2024
pulisher
Jul 24, 2024

Biodexa Pharmaceuticals Plc ADR (BDRX) is a good investment, but the stock may be undervalued - US Post News

Jul 24, 2024
pulisher
Jul 22, 2024

Balance Sheet Breakdown: Biodexa Pharmaceuticals Plc ADR (BDRX)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex

Jul 22, 2024
pulisher
Jul 19, 2024

Biodexa Pharmaceuticals sets $5 million offering - Investing.com

Jul 19, 2024
pulisher
Jul 17, 2024

Financial Metrics Check: Biodexa Pharmaceuticals Plc ADR (BDRX)’s Ratios for Trailing Twelve Months - The Dwinnex

Jul 17, 2024
pulisher
Jul 17, 2024

BDRX Stock Price and Chart — NASDAQ:BDRX - TradingView

Jul 17, 2024
pulisher
Jul 16, 2024

Are Smart Investors Making the Right Decision? Biodexa Pharmaceuticals Plc ADR (BDRX) - SETE News

Jul 16, 2024
pulisher
Jul 16, 2024

Biodexa’s Diabetes Drug Enters Phase 2a Studies - TipRanks

Jul 16, 2024
pulisher
Jul 12, 2024

The time has not yet come to remove your chips from the table: Biodexa Pharmaceuticals Plc ADR (BDRX) - SETE News

Jul 12, 2024
pulisher
Jul 12, 2024

Why Ericsson Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga

Jul 12, 2024
pulisher
Jul 11, 2024

Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session - Benzinga

Jul 11, 2024
pulisher
Jul 11, 2024

eRapa shows promise in Phase 2 for FAP treatment, Biodexa reveals - Investing.com

Jul 11, 2024
pulisher
Jul 11, 2024

BDRX’s Stock Market Adventure: -73.47% YTD Growth Amidst Volatility - The InvestChronicle

Jul 11, 2024
pulisher
Jul 11, 2024

Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI TractNow 12-Month Data - StockTitan

Jul 11, 2024
pulisher
Jul 10, 2024

Midatech Pharma PLC Announces Posting of Annual Report & Notice of AGM - Quantisnow

Jul 10, 2024
pulisher
Jul 10, 2024

Midatech Pharma PLC Announces Business Update - Quantisnow

Jul 10, 2024
pulisher
Jul 10, 2024

Midatech Pharma PLC Announces Fast Track Designation for MTX110 Development - Quantisnow

Jul 10, 2024
pulisher
Jul 10, 2024

Midatech Pharma PLC Announces IND Application for MTX110 Study in GBM Effective - Quantisnow

Jul 10, 2024
pulisher
Jul 10, 2024

Midatech Pharma PLC Announces Receipt of NASDAQ Notification - Quantisnow

Jul 10, 2024

Biodexa Pharmaceuticals Plc Adr (BDRX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
자본화:     |  볼륨(24시간):